| Odds Ratio | 95%CI | P value |
---|---|---|---|
NL Group a | Â | Â | Â |
HDL-ApoCIII | 1.49 | 1.12–1.99 | 0.006 |
VLDL-ApoCIII | 0.74 | 0.53–1.01 | 0.06 |
HDL-ApoCIII/ VLDL-ApoCIII | 1.85 | 1.14–2.89 | 0.01 |
Men | 2.76 | 1.57–3.48 | 0.005 |
Women | 1.65 | 1.06–2.33 | 0.02 |
ApoAI | 0.62 | 0.46–0.84 | 0.002 |
HTG Group a | Â | Â | Â |
HDL-ApoCIII | 2.00 | 1.05–3.80 | 0.04 |
VLDL-ApoCIII | 0.79 | 0.45–1.41 | 0.43 |
HDL-ApoCIII/ VLDL-ApoCIII | 2.52 | 0.76–5.98 | 0.02 |
Men | 3.17 | 1.14–3.94 | 0.005 |
Women | 1.55 | 1.04–1.89 | 0.03 |
HC Group a | Â | Â | Â |
HDL-ApoCIII | 1.56 | 1.18–2.05 | 0.002 |
VLDL-ApoCIII | 0.74 | 0.61–0.90 | 0.003 |
HDL-ApoCIII/ VLDL-ApoCIII | 1.78 | 1.23–2.67 | 0.003 |
Men | 1.96 | 1.26–2.67 | 0.005 |
Women | 1.23 | 1.06–1.89 | 0.01 |
ApoAI | 0.72 | 0.55–0.93 | 0.01 |
HLP Group a | Â | Â | Â |
HDL-ApoCIII | 0.90 | 0.64–1.28 | 0.57 |
VLDL-ApoCIII | 0.66 | 0.54–0.81 | <0.0001 |
HDL-ApoCIII/ VLDL-ApoCIII | 1.57 | 1.01–2.24 | 0.01 |
Men | 1.80 | 1.26–2.72 | 0.004 |
Women | 1.25 | 0.94–1.88 | 0.02 |
TG | 0.96 | 0.94–0.99 | 0.005 |
TC | 1.16 | 1.04–1.30 | 0.006 |
LDL-C | 0.83 | 0.73–0.94 | 0.004 |
ApoAI | 0.21 | 0.07–0.68 | 0.009 |
All Subjects, Final Modelb | Â | Â | Â |
HDL-ApoCIII/ VLDL-ApoCIII | 2.04 | 1.46–2.84 | <0.0001 |
Female sex | 0.26 | 0.10–0.66 | 0.0043 |
Age | 1.06 | 1.02–1.10 | 0.0063 |
TC | 1.04 | 1.01–1.06 | 0.002 |
TG | 0.99 | 0.99–1.00 | <0.0001 |
LDL-C | 0.99 | 0.98–1.00 | 0.01 |
HDL-C | 0.95 | 0.90–1.00 | 0.03 |
ApoB | 1.46 | 1.25–1.70 | <0.0001 |
ApoAI | 0.66 | 0.55–0.80 | <0.0001 |